Repligen Corporation (NASDAQ:RGEN) will issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Repligen Corporation has set its FY17 guidance at $0.57-0.62 EPS.

Repligen Corporation (NASDAQ:RGEN) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. Repligen Corporation’s revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.16 EPS. On average, analysts expect Repligen Corporation to post $0.59 EPS for the current fiscal year and $0.74 EPS for the next fiscal year.

Repligen Corporation (NASDAQ RGEN) opened at 37.11 on Wednesday. The firm has a 50-day moving average price of $40.19 and a 200 day moving average price of $39.90. The firm has a market capitalization of $1.39 billion, a P/E ratio of 72.62 and a beta of 1.18. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81.

Several equities research analysts have commented on the company. BidaskClub upgraded Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Saturday, August 12th. Jefferies Group LLC restated a “hold” rating and set a $40.00 price target on shares of Repligen Corporation in a research note on Thursday, October 19th. TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Finally, Stephens restated an “overweight” rating and set a $50.00 price target on shares of Repligen Corporation in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Repligen Corporation currently has a consensus rating of “Buy” and an average price target of $45.40.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/25/repligen-corporation-rgen-set-to-announce-quarterly-earnings-on-wednesday.html.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Earnings History for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.